Evidence map›Paper›PMID 41315262›Full record

ArticleNature communications2025

Benchmarking DNA foundation models for genomic and genetic tasks.

Haonan Feng, Lang Wu, Bingxin Zhao, Chad Huff, Jianjun Zhang, Jia Wu, Lifeng Lin, Peng Wei, Chong Wu

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Haonan FengDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Lang WuDepartment of Interdisciplinary Oncology and Department of Genetics, LSU-LCMC Health Cancer Center, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, 70112, USA.
Bingxin ZhaoDepartment of Statistics and Data Science, University of Pennsylvania, Philadelphia, PA, 19104, USA.ORCID http://orcid.org/0000-0002-0979-7891
Chad HuffDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Jianjun ZhangDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0001-7872-3477
Jia WuDepartment of Imaging Physics, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0001-8392-8338
Lifeng LinDepartment of Epidemiology and Biostatistics, University of Arizona, Tucson, AZ, 85724, USA.ORCID http://orcid.org/0000-0002-3562-9816
Peng WeiDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. pwei2@mdanderson.org.ORCID http://orcid.org/0000-0001-7758-6116
Chong WuDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. cwu18@mdanderson.org.ORCID http://orcid.org/0000-0002-8400-1785

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular CarcinomaP50CA217674 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BERETTA, LAURA, KASEB, AHMED · 2019 to 2023
$11.3M
Project 3: Identifying Molecular Vulnerabilities to Improve Interferon Gene Therapy in Bladder CancerP01CA296429 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BOGDAN A CZERNIAK, David J. McConkey · 2025 to 2026
$6.1M
Uncovering causal protein markers to improve prostate cancer etiology understanding and risk prediction in Africans and EuropeansR01CA263494 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI Chong Wu, Lang Wu · 2022 to 2026
$3.5M
Uncovering Causal Protein Markers to Characterize Pancreatic Cancer Etiology and Improve Risk PredictionU01CA293883 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI WU, CHONG, WU, LANG · 2024 to 2025
$1.4M
High-dimensional Mediation Analysis of Cardiovascular Traits with Multi-omics DataR21HL170213 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WEI, PENG · 2024 to 2025
$243k
NCI NIH HHS P01 CA296429NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA217674NCI NIH HHS R01 CA263494NCI NIH HHS U01 CA293883NHLBI NIH HHS R21 HL170213U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) U01CA293883
6 · The paper itself

Abstract

The rapid evolution of DNA foundation models promises to revolutionize genomics, yet comprehensive evaluations are lacking. Here, we present a comprehensive, unbiased benchmark of five models (DNABERT-2, Nucleotide Transformer V2, HyenaDNA, Caduceus-Ph, and GROVER) across diverse genomic and genetic tasks including sequence classification, gene expression prediction, variant effect quantification, and topologically associating domain (TAD) region recognition, using zero-shot embeddings. Our analysis reveals that mean token embedding consistently and significantly improves sequence classification performance, outperforming other pooling strategies. Model performance varies among tasks and datasets; while general purpose DNA foundation models showed competitive performance in pathogenic variant identification, they were less effective in predicting gene expression and identifying putative causal QTLs compared to specialized models. Our findings offer a framework for model selection, highlighting the impact of architecture, pre-training data, and embedding strategies on performance in genomic and genetic tasks.

Indexed as

DNAGenomicsModels, GeneticBenchmarkingHumansQuantitative Trait LociSequence Analysis, DNADNA

Identifiers

PMID41315262
PMCPMC12663285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.